Title of Invention

"METHOD OF DETECTING HUMAN PAPILLOMA VIRUS BY USING NUCLEIC ACID AMPLIFICATION METHOD AND NUCLEIC ACID CHAIN-IMMOBILIZED CARRIER"

Abstract

The invention relates to a nucleic acid primer for Lamp amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, comprising a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.

Full Text

DESCRIPTION METHOD OF DETECTING HUMAN PAPILLOMA VIRUS BY USING NUCLEIC ACID AMPLIFICATION METHOD AND NUCLEIC ACID CHAIN-IMMOBILIZED CARRIER Technical Field The present invention relates to a nucleic acid primer sequence, a kit, and a nucleic acid chain-immobilized carrier for detection of human papilloma virus and identification of its genotype, and a method of detecting human papilloma virus by using a nucleic acid amplification method. Background Art Human papilloma virus (HPV) infection was reported as a cause of uterine cervical cancer in the 1980's, and in particular, the relationship between cancer malignancy and HPV genotype is attracting attention. HPV is also considered to be the cause of cancers other than uterine cervical cancer such as cancers of the genital organs and oral mucosa, and there has been a demand for a rapid and accurate method of. detecting HPV. Hitherto known were a method of detecting a malignant or benign genotype by using a DNA/RNA-recognizing antibody, and a method of amplifying a region containing a sequence characteristic to a genotype in polymerase chain reaction (PCR) and identifying the genotype finally by using a genotype-specific probe. However, the former method, which does not identify the genotype, is not applicable to the test for vaccine administration currently under development. Alternatively, the latter method of using the PCR method had disadvantages such as complicated procedure of pretreatment for example nucleic acid extraction, demand for a complex temperature-regulating device such as thermal cycler, and longer reaction period of two hours or more. In addition, the PCR method has a possibility that, if an incorrect complementary strand happens to be synthesized, the product may be used as a template in amplification, consequently leading to incorrect judgment. Actually, it is difficult to control specific amplification only with' a difference of one nucleotide at the terminal of a primer. For detection by using a DNA chip, gene products amplified by the PCR method are generally double-stranded chains. Thus, there emerged a problem that the complementary strands became competitors to the probe, lowering hybridization efficiency and detection sensitivity in the hybridization reaction with a probe. Accordingly, for example, a method of decomposing or separating the complementary strand is employed to make the target gene product into a single strand. However, these methods still have problems such as the higher cost and complicated procedure because of the use of enzymes or magnetic beads, and there exists a need for a new method replacing such conventional methods. Disclosure of Invention An object of the present invention is to provide a nucleic acid primer for detection of an HPV nucleotide sequence present in LAMP amplification products when principle of a LAMP method allowing simple and rapid detection of nucleic acids is applied, and an HPV-detection method using the nucleic acid primer. The inventions employed a method different from the PCR method, i.e., LAMP method, for identification of the HPV genotype. Thus, it is possible to identify the genotype easily. However, the LAMP products, which have complicated high-order structures, cause physical hindrance with the probe-bound support during hybridization, which in turn lead to deterioration of the hybridization efficiency (see, for example, JP-A 2005-095043(KOKAI)). Accordingly, in the present invention, the primer is so designed that the human papilloma virus-derived target sequence becomes located in the single-stranded loop region of the LAMP product, differently from before. According to one aspect of the present invention, there is provided a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype, the nucleic acid primer being selected from the following (a)-(f); (a) a nucleic acid primer containing, on the came chain, a sequence complementary to a sequence selected from those in a first sequence group listed in Table 1 and a sequence selected from those in a second sequence group listed in Table z; (b) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in z third sequence group listed in Table 3; (c) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the second sequence group and a sequence selected from those in the third sequence group; (d) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (a) , (b), and (c) , by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers (a), (b), and (c) ; (e) a nucleic acid primer containing a sequence selected from those in a fourth sequence group listed in Table 4 or a sequence complementary thereto; and (f) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (e), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers According to another aspect of the present invention, there is provided a method of detecting human papilloma virus and identifying its genotype, comprising a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers above and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes. According to yet another aspect of the present invention, there is provided a nucleic acid chain-immobilized support carrying an immobilized human papilloma virus- or genotype-specific nucleic acid chain for detection of human-papilloma-virus LAMP amplification products. Preferably, the nucleic acid chain immobilized is (g) a nucleic acid probe containing a sequence selected from those in a fifth sequence group listed in Table 5 or a sequence complementary thereto, or (h) a nucleic acid probe containing a sequence that differs from a selected sequence of one of the nucleic acid probe (g), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic "acid probe (g) . Brief Description of Drav.'ings FIG. 1 is a schematic chart showing an amplification method in a conventional LAMP method; FIG. 2 is a schematic chart showing amplification products obtained by the conventional LAMP method; FIG. 3 is a schematic chart showing an amplification method for producing a nucleic acid for measurement according to the present invention; FIG. 4 is a schematic chart showing nucleic acids for measurement according to the present invention; FIG. 5 is a schematic view illustrating an example of a DNA chip for identification of HPV genotype; FIG. 6 is a schematic view illustrating another example of the DNA chip for identification of HPV genotype; FIG. 7 is a chart showing an example of electrophoretic photographs after LAMP amplification; FIG. 8 is a chart showing another example of the electrophoretic photographs after LAMP amplification; FIG. 9 includes charts showing examples of results detected by a current-detecting DNA chip; FIG. 10 include charts showing examples of the electrophoretic photographs after LAMP amplification; and FIG. 11 is a chart showing an HPV sequence and regions usable as a primer or probe according to the present invention. Best MCCIP for Carrying Out the Invention An amplification method used in the present invention, the "LAMP method", is a kind of isothermal polymerase chain reaction, and uses 4 or 6 kinds of primers. The LAMP method is reported to be higher in amplification efficiency than the PCR method and also resistant to the influence by impurities in a sample. It is thus possible to detect human papilloma virus in a smaller amount easily with simple pretreatment of the sample. The primer design and amplification products obtained in the LAMP method will be described with reference to FIGS. 1 and 2. FIG. 1 shows a double strand DNA to be detected. Conventionally, a target sequence has been located in the center of a stem-and-loop structure of LAMP amplification products (FIG. 2). In amplifying and detecting the target sequence, a total of four kinds of primer sequences (FIP, F3, BIP, and B3 primers) are determined from the sequences located at both sides of the target sequence. The FIP and BIP primers each contain two regions (FIP = Flc + F2, BIP = B2 + Blc). A total of six regions used in these primers will be called primer regions below. LAMP amplification by using the four kinds of primers gives amplification products with the dumbbell-shaped stem-and-loop structure shown in FIG. 2, each of them being complementary to each strand of the DNA shown in Fin 1. The amplification mechanism is not dtiacribed here, but may be referred, for c::c~:ple, to in JP-A 2002-186781(KOKAI), On the other hand, in the present invention, the primers are designed such that the target sequence is placed in the single-stranded loop region, unlike the conventional target-sequence site shown in FIG. 2. Specifically as shown in FIG. 3, in the invention, six primer regions are so placed that the target sequence (any one of FPc, FP, BP, and BPc in FIG. 3) is located between primer regions Fl and F2 (including F2 region), between primer regions F2c and Flc (including F2c region), between primer regions Bl and B2 (including B2 region), and/or between primer-regions B2c and Blc (including B2c region). The target sequence may be placed in any one of the single-stranded loop regions formed between the regions above, and thus, the loop region between primer regions Fl and F2 includes the F2 region. A part of LAMP amplification products, which is shown in FIG. 4, are obtained by preparing four kinds of primers according to the six primer regions thus determined and performing LAMP amplification by using these primers. In the LAMP amplification products, target sequences FPc, FP, BP, and BPc are located in the single-stranded loops in the dumbbell structure of the amplification products. On the other hand, primer regions Flc and Fl, and Blc and Bl, have sequences complementary to each other, and thus, IOMM double strands by selfhybridization. Some of the target sequences contained in the amplification products are in the single stranded state as shown in FIG. 4. For this reason, it is possible to detect the target sequences by specific hybridization to probe nucleic acids (FP, FPc, BP, and BPc) complimentary to respective target sequences without denaturation processing, as shown in the figure. The term "specific hybridization" means that it is possible to detect a slight difference caused by single nucleotide polymorphism (SNP) or mutation if present. The present invention detects the genotype of HPV virus by applying such a primer structure to HPV virus. A sequence shown in FIG. 11 is an HPV virus sequence. A region containing SEQ ID Nos. 1, 2 and 3 in the figure is known to be preserved among many HPV viruses. Alternatively, the SEQ ID No. 4 shows a region where it is known that there is polymorphism between malignant and benign tumors. In detecting the HPV viral genotype, polymorphism is detected, for example, by using a sequence of the region corresponding to the SEQ ID No. 4 as a target sequence. In such a case, for example, sequences selected from first sequence group (Table 1) and second sequence group (Table 2), or for example sequences selected from first sequence group and third sequence group (Table 3), are used as the sequence corresponding to the primer regions Fl and F2. The first, second, and third sequence groups are the sequence groups shown in the following Tables 1 to 3, and respectively correspond to the regions of SEQ ID No. 1, 2, and 3 in FIG. 11. The sequence in these regions varies according to its viral type, and is not always identical with the sequence shown in FIG. 11. In addition, z primer set consisting of BIP and B3 primers is also needed in actual LAMP amplification. It is possible to use the sequences of SEQ ID Nos. 5 and 6 in FIG. 11 or the complementary sequences thereof. The primer according to the invention for use is preferably a primer having, on the same chain in the direction from 5' to 3', a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in the second sequence group bound to each other, a sequence selected from those in the second sequence group and a sequence complementary to a sequence selected from those in the first sequence group bound to each other, a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in the third sequence group bound to each other, a sequence selected from those in the third sequence group and a sequence complementary to a sequence selected from those in the first sequence group bound to each other, a sequence complementary Lo a sequence selected from those in the second sequence group and a sequence selected from those in the third sequence group bound to each other, a sequence selected from those in the third sequence group and a sequence complementary to a sequence selected from those in the second sequence group bound to each other, a sequence selected from those in the fourth sequence group (Table 4), or a sequence complementary to a sequence selected from those in the fourth sequence group. The complementary sequences include strictly complementary sequences and also sequences that can hybridize under a condition stringent to the sequence groups above. Generally under such a condition, a sequential homology of 90 to 95% seems to be sufficient for progress of the reaction. Such a stringent condition would be obvious for those skilled in the art, and is, for example, a temperature in the range of 20°C to 65°C, 2 x SSC buffer solution, and 0.1% w/v SDS. Particularly favorable is a highly stringent condition at a temperature of at least 65°C, 0.1 x SSC buffer solution, and 0.1% w/v SDS. Alternatively, the sequence may be sequences of at least one of the strands of SEQ ID Nos. 1, 2 and 3 or the complementary strands thereof that have one or more nucleotides (e.g., 1 to 5 nucleotides) thereof substituted, deleted, or inserted. However, these substituted, deleted, or inserted sequences are sequences that can hybridize respectively with the complementary strands of unsubstituted, undeleted, or uninserted sequences under the stringent condition. In addition, at least one of SEQ ID Nos. 1, 2 and 3 and the complementary strands thereof may be a mixed-nucleotide sequence of 1 to 5 nucleotides, or at least one of SEQ ID Nos. 1, 2 and 3 and the complementary strands thereof may be a sequence of 1 to 5 nucleotides bring a universal nucleotide. Examples of the universal nucleotides for use include deoxyinosine (dI), and 3-Nitropyrrole, 5-Nitroindole, deoxyribofuranosyl (dP) , deoxy-5'-dimethoxytrityl-D-ribofuranosyl (dK) available from Gren Research. It would be obvious for those skilled in the art that these primer regions may be bound to each other directly or via a spacer in the primer according to the invention. A sequence (spacer) of about 1 to 100 nucleotides, preferably 2 to 30 nucleotides, may be present between the sequences or at the terminal of the primer. The length of the nucleic acid primer is about 15 to 200 nucleotides, preferably 20 to 100 nucleotides, and more preferably 40 to 60 nucleotides. It is possible to amplify the polymorphic region only by using sequences in combination of those in the sequence groups 1 to 3 or in the sequence group 4 as the sequence corresponding to the primer regions Fl and F2, or Bl and B2 in the primer for detection of HPV viral genoLype according to the present invention - It is thus possible to detect the polymorpnism present in SEQ ID No. 4 contained in LAMP amplification product with the probe. Accordingly, the target sequence FPc, FP, BP, or BPc located in the single-stranded loop of the dumbbell structure of the product amplified with the LAMP primer correspond to the sequence of SEQ ID No. 4. As described in FIG. 4, it is possible to obtain an HPV-derived target sequence (i.e., sequence in the region corresponding to SEQ ID No. 4) contained in a single-stranded loop structure of a amplification product having a stem-and-loop structure, by amplification by the LAMP method of an HPV-containing sample with the above-mentioned primers in the structure having primer regions Fl and F2. The amplification reaction may be carried out by using one primer set per tube or multiple primer sets for various genotypes per tube. It is more efficient to use the latter method for identification of multiple genotypes at the same time. The amplification products are detected, for example, by using probe nucleic acids (FP, FPc, BP, and BPc) having a sequence complementary to the SEQ ID No. 4. Homogeneous hybridization is achieved by using nucleic acid probe labeled by such as fluorochrome (Fluorescein, Rhodamine, FITC, FAM, TET, JOE, VIC, MAX, ROX.- HEX, TAMRA, Cy3," Cy5, TexacRed, etc.), quencher(TAMRA, Eclipoe, babcyl, Au colloid, etc.), electron spin material and metal complex(Ruthenium, Cobalt, Iron, etc.). For example molecular beacon, fluorescence resonance energy transfer (FRET) and electron spin resonance (ESR) technologies are often used for homogeneous hybridization using labeled probe. Invader and pyrosequenching technologies are also used for homogeneous hybridization without labeling. Homogeneous hybridization assay for LAMP products is not particularly limited. The probe nucleic acids may be immobilized on the surface of a solid support for heterogeneous hybridization, and typically, a DNA chip is used, but a probe on another microarray may be used. As described above, the region of the SEQ ID No. 4 is a polymorphic region, and thus, the probe nucleic acids for detection of amplified products may be altered according to the polymorphism to be detected. The nucleic acid probe sequence for use in the present invention is preferably a nucleic acid probe having a sequence containing a sequence selected from those in the fifth sequence group (Table 5) or a sequence complementary to a sequence selected from those in the fifth sequence group, or the sequence selected from those in the fifth sequence group or the sequence of the complementary to a sequence thereof of which one or more nucleotides are substituted, deleted or insertion. it is also possible to use trie sequences described in Kieter et ai., J. Clin. Microbiol., 37, 2508-17 (1999); Vernon et al., BMC Infectious Diseases, 3:12 (2003); JP-A 09-509062(KOKAI) and others. The structure of the nucleic acid probe is also not particularly limited, and DNA, RNA, PNA, LNA, methyl phosphonate-skeleton nucleic acid, and other synthetic nucleic acid chains may also be used. In addition, the chimeric nucleic acids thereof may also be used. It is also possible to introduce a functional group such as amino group, thiol group, or biotin, for immobilization of the nucleic acid probe on a solid support, and a spacer may also be introduced additionally between the functional group and the nucleotide. The kind of the spacer used herein is not particularly limited, and, for example, an alkane or ethylene glycol skeleton may be used. Examples of the universal nucleotides for use in the present invention include deoxyinosine (dl) and 3-Nitropyrrole, 5-Nitroindole, deoxyribofuramsyl (dP), and deoxy-5'-dimethoxytrityl-D-ribofuranosyl (dK) available from Gren Research, and the like. The detection method for use in the invention is not particularly limited, and examples thereof include optical methods of using turbidity, visible light, fluorescence, chemiluminescence, electrochemiluminescence, chemifluorescence, fluorescent energy transfer, ESR, or the like, and electrical methods of using an electrical property such as electrical current, voltage, frequency, conductivity, or resistance. The support for immobilizing the nucleic acid probe for use in the invention is not particularly limited, and examples thereof include particles (e.g., resin beads, magnetic beads, metal fine particles, and gold colloid), plates (e.g., microtiter plate, glass plate, silicon plate, resin plate, electrode plate, and membrane), and the like. The raw material for the support for use in the invention is not particularly limited, and examples thereof include permeable materials such as a porous material and membrane and"non-permeable materials such as glass and resin. Typical examples of the support materials include inorganic insulation materials such as glass, quartz glass, alumina, sapphire, forsterite, silicon carbide, silicon oxide, and silicon nitride, and organic materials such as polyethylene, ethylene, polypropylene, polyisobutylene, polymethyl methacrylate, polyethylene terephthalate, unsaturated polyesters, fluorine-containing resins, polyvinyl chloride, polychlorinated vinylidene, polyvinyl acetate, polyvinylalcohol, polyvinyl acetal, acrylic resins, polyacrylonitrile, polystyrene, acetal resins, polycarbonate, polyamide, phenol resins, urea resins, epoxy resins, melamine resins, styrene-acrylonitrile copolymers, acylonitra1e butadiene styrene copolymers, silicone resins polypnenyleneoxide, polysulfone, polyethylene glycol, agarose, acrylamide, nitrocellulose, nylon, and latex. The support surface on which the nucleic acid chain is immobilized may be formed, for example, with an electrode material. The electrode material is not particularly limited, but examples thereof include pure metals such as gold, gold alloys, silver, platinum, mercury, nickel, palladium, silicon, germanium, gallium, and tungsten, and the alloys thereof; carbon materials such as graphite and glassy carbon; and the oxides and compounds thereof. Other examples include semiconductor compounds such as silicon oxide, and various semiconductor devices such as CCD, FET, and CMOS. The electrode can be produced by plating, printing, sputtering, vapor deposition, or the like. An electrode film may be formed in vapor deposition by resistance heating, high-frequency heating, or electron beam heating. When in sputtering, the electrode film may be formed by DC bipolar sputtering, bias sputtering, asymmetric AC sputtering, getter sputtering, or high-frequency sputtering. It is also possible to use an electrolytic-polymerization membrane such as polypyrrole or polyaniline or a conductive polymer. The material for insulating the area other than the electrode is not particularly limited, but preferably, a photopolymer or a photoresist material. Examples of the resist materials for use include photoresists for light irradiation, photoresists for far-ultraviolet light, photoresists for X-ray irradiation, and photoresists for electron beam irradiation. Examples of the photoresists for light irradiation include photoresists containing cyclized rubber, poiycinnamic acid or novolak resin as the main raw material. A cyclized rubber, a phenol resin, polymethylisopropenylketone (PMIPK), polymethyl methacrylate (PMMA), or the like is used as the far-ultraviolet photoresist. Any one of COP, metal acrylate, as well as the substances described in the Thin Film Handbook (published by Ohmsha) may be used for the X-ray resist. Further, the substances described in the literature above such as PMMA may be used for the electron-beam resist. The resist for use desirably has a thickness of 100A or more and 1 mm or less. It is possible to make the area constant by covering the electrode with a photoresist and performing lithography. It is thus possible to uniformize the amount of DNA probe immobilized between electrodes and to make the measurement favorable in reproducibility. The resist material has been generally removed finally, but it is possible to use the resist material as a part of the electrode for gene detection without removal. In such a case, a substance higher- in water resistance is needed to De uspd as the resist material. Materials other than the photoresist materials may be used for the insulation layer formed over the electrode. Examples thereof include oxides, nitrides, and carbides of metals such as Si, Ti, Al, Zn, Pb, Cd, W, Mo, Cr, Ta, and Ni and the alloys thereof. After a thin film is formed on the material, for example, by sputtering, vapor deposition, or CVD, the electrode-exposed regions are patterned to an area adjusted to a particular value by photolithography. It is possible to prepare an electrode allowing tests on several kinds of targets by configuring several electrode units and immobilizing different probes thereon on a single chip. It is also possible to test multiple samples at the same time by configuring several electrode units and immobilizing the same probe thereon on a single chip. In such a case, multiple electrodes are patterned on a substrate previously by photolithography. It is effective then to form an insulation film separating individual electrodes for prevention of contact of neighboring electrodes. The thickness of the insulation film is preferably about 0.1 to 100 micrometers. The sample to be analyzed in the present invention is not particularly limited, and examples thereof include blood, serum, leukocyte, urine, feces, semen, saliva, vaginal fluid, tissue, biopsy sample, oral mucosa, cultured cell, sputum, -?.nd the like. Nucleic acid components are extracted from these samples. The extracting method is not particularly limited, and examples thereof include liquid-liquid extraction, for example with phenol-chloroform, and solid-liquid extraction by using a carrier. Commercial nucleic acid-extracting kits such as QIAamp (manufactured by QIAGEN) , or Sumai test (manufactured by Sumitomo Metal Industries) may be used instead. The extracted nucleic acid components are amplified by LAMP methods, and the amplified product is hybridized with the probe immobilized on the electrode for gene detection. The reaction is carried out in a buffer solution at an ionic strength in the range of 0.01 to 5 and at a pH in the range of 5 to 10. Other additives such as hybridization accelerator dextran sulfate, salmon sperm DNA, bovine thymic DNA, EDTA, and surfactant may be added to the solution. The amplified product is added thereto. Alternatively, hybridization may be performed by dropping the solution on the substrate. The reaction may be accelerated, for example, by agitation or shaking during the reaction. The reaction temperature is preferably in the range of 10°C to 90°C, and the reaction period is about 1 minute or more to overnight. After hybridization reaction, the electrode is separated and washed. A buffer solution at an ionic strength of 0.01 to 5 and a pH in the range" of 5 to 10 is used for washing. The extracted nucleic acid sample can be detected, by labeling with a fluorescent dye such as FITC, Cy3, Cy5, or rhodamtine; biotin, hapten, an enzyme such as oxidase or phosphatase, or an electrochemically active substance such as ferrocene or quinone, or by using a second probe previously labeled with the substance described above. For example with an electrochemically active DNA-binding substance, nucleic acid components are analyzed in the following manner. A substrate is first cleaned, a DNA-binding substance selectively binding to the double-stranded region formed on the electrode surface is allowed to react, and the substrate is analyzed electrochemically. The DNA-binding substance for use is not particularly limited, and examples thereof include Hoechst 33258, acridine orange, quinacrine, daunomycin, metallointercalators, bisintercalators such as bisacridine, trisintercalators, and polyintercalators. In addition, these intercalators may be modified with an electrochemically active metallocomplex such as ferrocene or viologen. The concentration of the DNA-binding substance may vary according to the kind thereof, but is generally in the range of 1 ng/ml to 1 mg/ml. A buffer solution at an ionic strength in the range of 0.001 to 5 and a pH in the range of 5 to 10 is" used then. The electrode after reaction with the DNA-binding substance is washed and analyzed electrocnemically. The electrochemical measurement is performed in a three-electrode analyzer including reference, counter, and action electrodes or in a two-electrode analyzer including counter and action electrodes. During measurement, a voltage high enough to cause electrochemical reaction of the DNA-binding substance is applied, and the reaction current derived from the DNA-binding substance is determined. The voltage may be varied linearly, or may be applied in the pulse shape or at a constant voltage. The current and voltage during measurement are controlled by using a device such as a potentiostat, a digital multimeter, or a function generator. The concentration of the target gene is calculated from the measured electric current with a calibration curve. The gene-detecting device using the gene-detecting electrode includes a gene-extracting unit, a gene-reacting unit, a DNA-binding substance-reacting unit, an electrochemical measurement unit, a washing unit, and others. It is possible to diagnose human papilloma virus infection by using the method according to the present invention. Thus, provided is a method of diagnosing human papilloma viral infection, comprising obtaining a sample from human; extracting nucleic acid components frcir. the sample; a step of amplifying the nucleic acid chains in the sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers described above; and a step of analyzing whether there are amplification products after the amplification reaction, wherein presence of the amplification products indicates infection to human papilloma virus. Also provided is a method of diagnosing human papilloma virus infection, comprising obtaining a sample from human; * extracting nucleic acid components from the sample; a step of amplifying the nucleic acid chains in the sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers described above; and a step of analyzing whether there are amplification products or identifying the genotype of the virus after the amplification reaction, wherein presence of the amplification products leads to diagnosis of infection to human papilloma virus. In addition, the present invention provides a LAMP-amplification kit for use in the detection of human papilloma virus and identification of its genotype. The LAMP-amplification kit contains a nucleic acid primer selected from following (a)-(f) and additionally any other components needed for the LAMP amplification reaction such as polymerase, dNTPs, betaine, buffer, positive control DNA, and sterilized water: (a) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in a first sequence group listed in Table 1 and a sequence selected from those in a second sequence group listed in Table 2; (b) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in a third sequence group listed in Table 3; (c) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the second sequence group and a sequence selected from those in the third sequence group; (d) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (a), (b) , and (c), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers (a), (b), and (c), (e) a nucleic acid primer containing a sequence selected from those in a fourth sequence group listed in Table 4 or a sequence complementary -hereto; and (f) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (e), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers (e). In addition, the present invention provides a detection kit for use in the detection of human papilloma virus and identification of its genotype. The detection kit includes the above-mentioned LAMP-amplification kit and a support carrying a nucleic acid chain immobilized thereon for detection of the human-papilloma-virus LAMP amplification products amplified by using the LAMP-amplification kit. The immobilized nucleic acid chain is; (g) a nucleic acid probe containing a sequence selected from those in a fifth sequence group listed in Table 5 or a sequence complementary thereto, or (h) a nucleic acid probe containing a sequence that differs from a selected sequence of one of the nucleic acid probe (g), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid probe (g). The nucleic acid probe may be immobilized on the surface 01 a support, and the support and the support surface are made of the material described above. Examples Hereinafter, typical examples of the sequences corresponding to the primer regions in the first, second, third, and fourth sequence groups are shown in the following Tables. Table 1 Representative nucleic acid primer sequence (Table Removed) Table 2 (Table Removed) Table 3 (Table Removed) Table 4 (Table Removed) Table 4 (Table Removed) Table 4 (Table Removed) Table 4 (Table Removed) Table 4 (Table Removed) In addition, typical examples of th^ sequencer: in the fifth sequence group corresponding to the nucleic acid probe will be shown below. Table 5 (Table Removed) Hereinafter, the method of detecting a nu<_i acid according to the present invention will be described specifically with reference examples.> (1) Synthetic oligonucleotide A nucleic acid primer for use in the detection of human papilloma virus and identification of its genotype is prepared in combination of the sequences described in Table 1 above. More specifically, sequences in the first and the second sequence groups, sequences in the first and third sequence groups, or sequences complementary to the sequences in the second sequence groups and sequences in third sequence groups are bound to each other directly or via a spacer. Alternatively, a sequence in the fourth sequence group or a sequence complementary thereto is prepared. Any method known to those skilled in the art may be used in preparing the primers. (2) LAMP reaction solution The LAMP reaction solution had the composition shown in the following Table 6. The template used was a plasmid DNA containing cloned HPV16. Table 6 (Table Removed) In addition, the nucleic acid primer for LAMP amplification reaction shown in the following Table 7 was used as the same time. Table 7 Nucleic acid primer sequence for LAMP amplification (Table Removed) (3) Nucleic acid amplification by T.AMP method The nucleic acid amplification is carried out at a temperature of 58"C for 1 hour. A sample added with sterilized water instead of the template is used as the negative control. Analysis of the amplified LAMP products by agarose gel electrophoresis reveals a ladder-shaped pattern characteristic to LAMP products. On the other hand, no ainplif ication is observed with a sample containing no template DNA. It is thus possible to perform sequence-specific amplification of the papilloma virus by using a selected primer set. (4) Preparation of nucleic acid probe-immobilized slide glass (FIG. 5) The DNA probes 1-5 were immobilized on the slide glass 6. The nucleic acid sequence of them is shown in Table 8-1. Table 8-1 Probe sequence (Table Removed) The terminal is modified by amino group. HPV's 16 to 31 were used as sequences specific to the subtypes of HPV, while the rDNA's as negative controls. Each probe was modified with an amino group at the terminal, and was immobilized on a carbodiimide-treated slide glass substrate by spotting the probe solution thereon. Finally, Lhe substrate was washed with uitrapure water and air-dried, to give a DNA chip. (5) Hybridization of LAMP products to nucleic acid probe The LAMP products amplified in (3) above were used as a nucleic acid sample. The DMA chip prepared in (4) was hybridized by dipping it into the LAMP product solution containing 2 x SSC salt added and leaving it therein at 35°C for 60 minutes. Subsequently, Cy5-labelled nucleic acid of SEQ ID No. 7 was added thereto, and the mixture was left at 35°C for 15 minutes and washed with uitrapure water slightly. The fluorescence intensity was detected by using Tyhoon manufactured by Amersham. (6) Results Fluorescence measurement showed significant emission only on HPV16 probe-immobilized spots, indicating that it was possible to detect nucleic acids amplified by LAMP reaction specifically to the sequence. (7) Preparation of nucleic acid probe-immobilized electrode (FIG. 6) The DNA probes 7-11 were immobilized on the electrode 13 placed on the support 12. The nucleic acid sequence of them is shown in Table 8-2. Connection part 14 may be placed on the support 12. Table 8-2 Probe sequence (Table Removed) *The terminal is modified by thiol group. HPV's 16 to 31 are used as sequences specific to the subtypes of HPV, while the rDNA's as negative controls. Each probe is modified with an amino group at the terminal, and is immobilized cm a gold electrode by spotting the probe solution thereon. Finally, the substrate is washed with ultrapure water and air-dried, to give a DNA chip. (8) Hybridization of LAMP products to nucleic acid probe The DNA chip prepared in (7) is hybridized by dipping it into the LAMP product solution containing added 2 x SSC salt and leaving it therein at 35°C for 60 minutes. The electrode is dipped into a phosphate buffer solution containing a 50 µM intercalating agent Hoechst 33258 for 15 minutes, and the oxidative current response of the Hoechst 33258 molecule is determined. (9) Result Voltammetric analysis indicates that significant current signals are detectable only on the spots carrying the immobilized HPV16 probe. For this reason, it has been clear that it is possible to detect nucleic acids amplified by LAMP reaction sequerce-speuifically. (10) Multiamplification by LAMP method 1 Amplification according to a kind of template was performed by using the primer shown in Table 9. As a result, a ladder-shaped band characteristic to LAMP amplification was observed, and genotype-specific amplification was confirmed (FIG. 7). Then, amplification according to a kind of template by using multiple primers, i.e., multiple mixed primer sets respectively in groups A to D, confirmed genotype-specific amplification (FIG. 8). Table 9 (Table Removed) (11) Detection of LAMP multiamplification products 1 The amplification products shown in FIG. 8 were detected by using a current-detecting DNA chip carryi the probes of sequence numbers 605, 623, 635, 652, 683, 763, and 793 immobilized on tne same chip. The probes are designed to react specifically with the nucleic acids of sequence numbers of 16, 18, 31, 33, 45, 58, and 68, respectively. Reaction of the sample amplified only by using the templates 16 and 18 resulted in increase in current only on the electrodes corresponding to the templates, indicating genotype-specific detection (FIG. 9). (12) Multiamplification by LAMP method 2 Primer sets of groups A to D shown in Table 10 were mixed respectively to give multiple primer sets. The amplification of a kind of template was performed by using the multiple primer sets. The amplification was performed at a template concentration of 10-3 copies/reaction at 65 degrees for 2 hours. As a result, genotype-specific amplification was confirmed (FIG. 10). Table 10 (Table Removed) (13) Detection, of LAMP multiamplif ication products 2 The amplification products shown in FIG. 10 were detected by using a current-detecting DNA chip carrying the probes of" SEQ ID rio. 602.- 623, 635, 647, 657, 681, 694, 750, 762, 774, and 793 immobilized on the same chip. The probes are designed to react specifically with tne nucleic acids of sequence numbers of 16, 18, 31,- 33, 35, 45, 51, 56, 58, 59, and 68, respectively. Reaction of the sample obtained by amplification by using each of the 11 kinds of templates resulted in increase in current only on the electrode corresponding to the template, indicating genotype specific detection of 11 kinds of genotypes. (14) Multiamplification by LAMP method 3 Primer sets of groups A to D shown in Table 11 were mixed respectively to give multiple primer sets. Specifically, tube A contains primer sets with primers 16, 35, and 59; tube B contains a primer set with primers 18, 39, and 56; tube C contains a primer set with primers 45, 51, 58, and 68; and tube D contains a primer set with primers 31, 33, and 52. Further, tube E contained primers of SEQ ID Nos. 801, 802, 803, and 804 prepared for amplification of human p-globin gene (Table 12). The amplification of a kind of template was performed by using the multiple primer sets respectively. A plasmid corresponding to each HPV type was used as the template, and the hybridization was performed at a concentration of 103 copies/reaction at 63°C for 1.5 hours, which confirmed genotype-specific amplification. Table 11 (Table Removed) (15) Detection cf LAMP multiamplification product3 3 The amplification products above were detected by using a current-detecting DNA chip carrying the probes of SEQ ID Nos. 600, 623, 630, 641, 654, 673, 676, 699, 725, 750, 752, 771, and 783 on a single chip. These probes are designed to react specifically with the sequences of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, respectively. The oligonucleotide of SEQ ID No. 813 as a probe for detecting ß -globin gene was immobilized as the positive control of reaction, and the oligonucleotide of SEQ ID No. 814 was immobilized as the negative control on the same substrate (Table 13). Reaction of the sample obtained by amplification by using each of the 13 kinds of templates resulted in increase in current only on the electrode corresponding to the template, indicating genotype specific detection of the 13 kinds of genotypes. Table 13 (Table Removed) Additional advantages and modifications will readily occur to those skilled in the art. Therefore, the invention in its broader aspects is not limited to the specific details and representative embodiments shown and described herein. Accordingly, various modifications may be made without departing from the spirit or scope of the general inventive concept as defined by the appended claims and their equivalents. We claim: 1. A set of nucleic acid primers for LAMP amplification for use in the detection of genotypes of human papilloma virus, the set is selected from the group consisting of: Set 1 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 136, 132, 126, 128 and 138 respectively; Set 2 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 278, 276, 277, 281 and 280 respectively; Set 3 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 527, 524, 526, 523 and 529.respectively; Set 4 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 164, 167, 162, 166 and 170 respectively; Set 5 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 320, 327, 319, 324 and 328 respectively; Set 6 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 454, 457, 453, 456 and 458 respectively; Set 7 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 363, 359, 366, 361 and 370 respectively; Set 8 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 399, 391, 395, 388 and 402 respectively; Set 9 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 474, 476, 477, 475 and 480 respectively; Set 10 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 549, 547, 548, 546 and 572 respectively; Set 11 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 208, 203, 210, 205 and 214 respectively; Set 12 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 251, 244, 248, 242 and 255 respectively; and Set 13 consisting of five nucleic acid primers consisting of a sequence of SEQ ID Nos. 422, 425, 420, 429 and 431 respectively. 2. A mixture of primer sets for LAMP multiamplification for use in detection genotypes of human papilloma virus, the mixture is selected from the group consisting of: Mixture A comprising Set 1, 2 and 3 as claimed in claim 1; Mixture B comprising Set 4, 5 and 6 as claimed in claim 1; Mixture C comprising Set 7, 8, 9 and 10 as claimed in claim 1; and Mixture D comprising Set 11,12 and 13 as claimed in claim 1. 3. A kit for detection of genotypes of human papilloma virus, comprising at least one of Primer-Probe Set selected from the group consisting of: Primer-Probe Set 1 consisting of the Set 1 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 600 and 597 respectively, Primer-Probe Set 2 consisting of the Set 2 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 654, Primer-Probe Set 3 consisting of the Set 3 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 771 and 768 respectively, Primer-Probe Set 4 consisting of the Set 4 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 623, Primer-Probe Set 5 consisting of the Set 5 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 673 and 667 respectively, Primer-Probe Set 6 consisting of the Set 6 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 750 and 741 respectively, Primer-Probe Set 7 consisting of the Set 7 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 676, Primer-Probe Set 8 consisting of the Set 8 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 699 and 684 respectively, Primer-Probe Set 9 consisting of the Set 9 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 752, Primer-Probe Set 10 consisting of the Set 10 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 783, Primer-Probe Set 11 consisting of the Set 11 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 630, Primer-Probe Set 12 consisting of the Set 12 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 641, and Primer-Probe Set 13 consisting of the Set 13 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 725 and 713 respectively. 4. The kit as claimed in claim 3, wherein the nucleic acid probe is immobilized on a support surface. 5. The kit as claimed in claim 4, wherein the support surface is an electrode. 6. A method of detecting genotypes of human papilloma virus, comprising: a step of obtaining an amplification product by LAMP amplification of a nucleic acid chains in a sample by using nucleic acid primers; a step of hybridizing the amplification product with a nucleic acid probe; and a step of detecting double-stranded chains formed by the hybridization to detect human papilloma virus or identifying its genotype; wherein the nucleic acid primers and the nucleic acid probe is comprised a Primer-Probe Set selected from the group consisting of: Primer-Probe Set 1 consisting of the Set 1 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 600 and 597 respectively, Primer-Probe Set 2 consisting of the Set 2 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 654, Primer-Probe Set 3 consisting of the Set 3 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 771 and 768 respectively, Primer-Probe Set 4 consisting of the Set 4 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 623, Primer-Probe Set 5 consisting of the Set 5 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 673 and 667 respectively, Primer-Probe Set 6 consisting of the Set 6 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 750 and 741 respectively, Primer-Probe Set 7 consisting of the Set 7 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 676, Primer-Probe Set 8 consisting of the Set 8 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 699 and 684 respectively, Primer-Probe Set 9 consisting of the Set 9 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 752, Primer-Probe Set 10 consisting of the Set 10 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 783, Primer-Probe Set 11 consisting of the Set 11 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 630, Primer-Probe Set 12 consisting of the Set 12 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 641, and Primer-Probe Set 13 consisting of the Set 13 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 725 and 713 respectively. 7. The method as claimed in claim 6, wherein the nucleic acid probe is immobilized on a support surface. 8. The method as claimed in claim 7, wherein the support surface is made of an electrode material. 9. The method as claimed in claim 8, wherein an electrochemically active nucleic acid chain-recognizing agent is used in the step of detecting double-stranded chains. 10. A kit for detection of genotypes of human papilloma virus, characterized by comprising at least one of Detection Set selected from the group consisting of Detection set A, B, C, and D, wherein: Detection Set A comprises at least one Primer-Probe Set selected from the group consisting of: Primer-Probe Set 1 consisting of the Set 1 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 600 and 597 respectively, Primer-Probe Set 2 consisting of the Set 2 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 654, Primer-Probe Set 3 consisting of the Set 3 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 771 and 768 respectively, Detection Set B comprises at least one Primer-Probe Set selected from the group consisting of: Primer-Probe Set 4 consisting of the Set 4 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 623, Primer-Probe Set 5 consisting of the Set 5 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 673 and 667 respectively, Primer-Probe Set 6 consisting of the Set 6 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 750 and 741 respectively, Detection Set C comprises at least one Primer-Probe Set selected from the group consisting of: Primer-Probe Set 7 consisting of the Set 7 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 676, Primer-Probe Set 8 consisting of the Set 8 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 699 and 684 respectively, Primer-Probe Set 9 consisting of the Set 9 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 752, Primer-Probe Set 10 consisting of the Set 10 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 783, and Detection Set D comprises at least one Primer-Probe Set selected from the group consisting of: Primer-Probe Set 11 consisting of the Set 11 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 630, Primer-Probe Set 12 consisting of the Set 12 as claimed in claim 1 and a nucleic acid probe consisting of a sequence of SEQ ID No. 641, and Primer-Probe Set 13 consisting of the Set 13 as claimed in claim 1 and at least one nucleic acid probe consisting of a sequence of SEQ ID Nos. 725 and 713 respectively. 11. A kit for detection of genotypes of human papilloma virus, characterized by comprising at least one mixture of primer sets and DNA chip, wherein: the mixture is selected from the group consisting of: Mixture A comprising Set 1, 2 and 3 as claimed in claim 1; Mixture B comprising Set 4, 5 and 6 as claimed in claim 1; Mixture C comprising Set 7, 8, 9 and 10 as claimed in claim 1; and Mixture D comprising Set 11,12 and 13 as claimed in claim 1: and wherein: the DNA chip comprises nucleic acid probes consisting of a sequence of: one of SEQ ID Nos. 600 and 597; SEQ ID No. 654; one of SEQ ID Nos. 771 and 768; SEQ ID No. 623; one of SEQ ID Nos. 673 and 667; one of SEQ ID Nos. 750 and 741; SEQ ID No. 676; one of SEQ ID Nos. 699 and 684; SEQ ID No. 752; SEQ ID No. 783 SEQ ID No. 630; SEQ ID Nos. 641; and one of SEQ ID Nos. 725 and 713 respectively, and the nucleic acid probes are immobilized on a support surface.

Documents:

4921-delnp-2008-Abstract-(04-03-2013).pdf

4921-delnp-2008-abstract.pdf

4921-delnp-2008-Claims-(04-03-2013).pdf

4921-delnp-2008-Claims-(07-05-2014).pdf

4921-delnp-2008-claims.pdf

4921-delnp-2008-Correspondence Others-(04-03-2013).pdf

4921-delnp-2008-Correspondence Others-(07-05-2014).pdf

4921-delnp-2008-Correspondence-Others-(23-10-2012).pdf

4921-delnp-2008-correspondence-others.pdf

4921-delnp-2008-description (complete).pdf

4921-delnp-2008-Drawings-(04-03-2013).pdf

4921-delnp-2008-drawings.pdf

4921-delnp-2008-Form-1-(04-03-2013).pdf

4921-delnp-2008-form-1.pdf

4921-delnp-2008-Form-13-(04-03-2013).pdf

4921-delnp-2008-form-18.pdf

4921-delnp-2008-Form-2-(04-03-2013).pdf

4921-delnp-2008-form-2.pdf

4921-delnp-2008-Form-3-(07-05-2014).pdf

4921-delnp-2008-Form-3-(23-10-2012).pdf

4921-delnp-2008-form-3.pdf

4921-delnp-2008-form-5.pdf

4921-delnp-2008-GPA-(04-03-2013).pdf

4921-delnp-2008-pct-101.pdf

4921-delnp-2008-pct-210.pdf

4921-delnp-2008-pct-237.pdf

4921-delnp-2008-pct-306.pdf

4921-delnp-2008-pct-311.pdf